Some new drugs appear to have a limited potential for diffusion, but they may still cause serious harm. Stakeholders, including policy makers, practitioners and researchers, will increasingly need access to timely evidence-based information on new drugs
This abstract is provided here as a convenience only. Check the publisher's website (if available) for the definitive version.
There is a need to review the various regulatory options that are available in order to address the challenge presented by a plethora of new psychoactive substances appearing on the market as well as to address the technology for rapid development and marketing of new ones.